The study traced access to biomarker-matched therapy for metastatic colorectal cancer in Brazil's Unified Health System (SUS). In 459 colorectal tumours from The Cancer Genome Atlas, 51.4% were RAS wild-type, 16.6% MSI-high and 9.8% BRAF V600E. None of the matched therapies had been approved for national funding in SUS. Partitioned-survival models gave costs per QALY of R$314,000 for pembrolizumab, R$761,000 for cetuximab (exploratory) and R$836,000 for first-line BRAF-targeted therapy. No encorafenib price alone brought the BRAF regimen below the R$40,000 or R$120,000 thresholds. Meeting either threshold required joint 75-84% price cuts to encorafenib and cetuximab. Prevalence came from tumours of mixed stage, and survival data for the BRAF regimen were interim.
Why it is interesting: Common molecular targets in metastatic colorectal cancer do not translate into funded treatment in Brazil's public system. The analysis names a distinct barrier for each drug pathway, from pembrolizumab pricing to the two-drug BRAF combination.
Abstract — the authors' own words, CC BY
Background
Molecular targets are common in metastatic colorectal cancer, yet Brazil's Unified Health System (SUS) does not fund any biomarker-matched therapy. Where each pathway is interrupted-evidence, regulatory indication, incorporation, testing, or price-and what would overcome each barrier remain unclear. Methods
We quantified actionable biomarker prevalence in TCGA-COADREAD (n = 459), mapped each biomarker-therapy pathway across the Brazilian access chain using primary regulatory sources (2025 national protocol, CONITEC, ANVISA, SIGTAP), and developed partitioned-survival cost-utility models (SUS perspective, lifetime horizon, 5% annual discounting), conditional on biomarker-positive patients, evaluating first-line pembrolizumab (KEYNOTE-177), first-line cetuximab in left-sided RAS wild-type disease (CRYSTAL), and first-line encorafenib plus cetuximab plus mFOLFOX6 (BREAKWATER, interim survival), with second-line BEACON examined as a scenario. Drugs were costed at regulated government-purchase ceiling prices; results were assessed against Brazil's 2022 reference threshold of R$40,000/QALY, with the threefold value (R$120,000/QALY) as a scenario for specific circumstances. Results
In the mixed-stage TCGA-COADREAD cohort - characterizing theoretical molecular opportunity - RAS wild-type status was observed in 51.4%, MSI-high in 16.6%, and BRAF V600E in 9.8%, yet every matched pathway was interrupted at or before national incorporation. Incremental cost-effectiveness ratios were R$314,000/QALY for pembrolizumab, R$761,000/QALY for cetuximab (exploratory), and R$836,000/QALY for first-line BRAF-targeted therapy. No non-negative encorafenib price alone brought the BRAF regimen below either threshold; achieving cost-effectiveness would require joint reductions of 75-84% in encorafenib and cetuximab prices. Conclusion
Precision oncology in SUS is constrained not by target scarcity, but by pathway-specific barriers to incorporation and affordability. Policy summary
Different pathways require different policy responses: negotiated pricing for pembrolizumab, substantial class-level price reductions for anti-EGFR antibodies, and regimen-level negotiation covering both targeted agents in the BRAF combination. Identifying each pathway's barrier turns a generic affordability problem into a concrete target for health technology assessment and pricing decisions in middle-income health systems.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.